The U.S. Food and Drug Administration (FDA) approved a supplemental efficacy application for Leqvio (inclisiran) on February 12, 2026. This approval, designated NDA 214012 S-18, relates to an update in the drug's approved efficacy profile.
Background
Inclisiran, marketed as Leqvio, is a medication developed by Novartis. This supplemental approval pertains to an update in the drug's efficacy information, building upon its existing regulatory approvals. The original application for inclisiran was sponsored by Novartis.
What this means
A supplemental efficacy approval from the FDA indicates that new data has been reviewed and accepted, leading to an update in the drug's approved efficacy information. While specific details of this supplemental application (NDA 214012 S-18) were not immediately disclosed, such approvals commonly reflect new clinical trial findings, real-world evidence, or post-market surveillance data that further characterize the drug's benefits. These updates can be crucial for clinicians, providing a more comprehensive understanding of Leqvio's effectiveness in managing patient conditions. For researchers, it may highlight new avenues for study, and for patient advocates, it reinforces the ongoing evaluation and refinement of available treatments.
Source
The information regarding this supplemental efficacy approval for Leqvio (inclisiran) was sourced from the U.S. Food and Drug Administration (FDA) on February 12, 2026. The details are available on the accessdata.fda.gov website, specifically referencing NDA 214012.